NCT00474487已完成3 期
A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age.
Novartis Vaccines3 个研究点 分布在 2 个国家目标入组 2,831 人开始时间: 2007年5月最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2,831
- 试验地点
- 3
- 主要终点
- Number of Subjects With at Least One Severe Systemic Reaction, Ages 19 to 55 Years
研究概览
简要总结
This study will evaluate the safety and immune response of Novartis Meningococcal ACWY conjugate vaccine in healthy adolescents and adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •individuals who are 19-65 years of age inclusive and who, after the nature of the study has been explained have provided written informed consent
- •individuals who are available for all visits and telephone calls scheduled for the study;
- •individuals who are in good health
排除标准
- •individuals with a previous or suspected disease caused by N. meningitidis
- •individuals with previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
- •individuals with previous or suspected disease caused by N. meningitidis
- •individuals with any serious acute, chronic or progressive disease
- •individuals who are pregnant or breastfeeding
结局指标
主要结局
Number of Subjects With at Least One Severe Systemic Reaction, Ages 19 to 55 Years
时间窗: Days 1 to 7
Safety of the Novartis MenACWY conjugate vaccine and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of subjects presenting at least one severe systemic reaction during the first 7 days following a single vaccination in healthy subjects.
次要结局
- Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 19 to 55 Years), PP Population(1 month postvaccination)
- Summary of hSBA GMTs (Ages 56 to 65 Years), PP Population(1 month postvaccination)
- Number of Subjects With Local and Systemic Reactions, Ages 19 to 55 Years(Days 1 to 7)
- Number of Subjects With Local and Systemic Reactions, Ages 56 to 65 Years(Days 1 to 7)
- Percentage of Subjects With Seroresponse and hSBA ≥ 1:8 (Ages 56 to 65 Years), PP Population(1 month postvaccination)
- Summary of hSBA GMTs (Ages 19 to 55 Years), PP Population(1 month postvaccination)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsMeningitis, MeningococcalNCT00474526Novartis Vaccines4,545
已完成
3 期
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In AdolescentsMeningococcal MeningitisHuman Papillomavirus InfectionTetanusPertussisNCT00518180Novartis Vaccines1,620
已完成
3 期
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaMeningococcal DiseaseNCT01725217Novartis Vaccines198
已完成
3 期
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in IndiaBacterial MeningitisNCT01547715Novartis180
已完成
3 期
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in TaiwanBacterial MeningitisNCT01410474Novartis341